Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02134288 · ClinicalTrials.gov registry record · Early Phase 1
Belatacept for Renal Transplant Recipients With Delayed Graft Function
A Early Phase 1 study, sponsored by Ohio State University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT02134288 is a Early Phase 1 study that was terminated before completion, run by Ohio State University. The registered enrollment target is 8 participants.
The verdict
NCT02134288, a Early Phase 1 study, was terminated before completion, sponsored by Ohio State University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Currently looking for individuals that have received a kidney transplant, are experiencing delayed graft function (DGF), and meet the criteria for study participation.
Interventions
- DRUG Everolimus
- DRUG Belatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-04 |
| Est. Completion | 2019-01-18 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02134288
The ClinicalTrials.gov registry entry for NCT02134288 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT02134288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02134288 about?
NCT02134288 is a clinical study titled "Belatacept for Renal Transplant Recipients With Delayed Graft Function". Currently looking for individuals that have received a kidney transplant, are experiencing delayed graft function (DGF), and meet the criteria for study participation.
What is the current status of trial NCT02134288?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2014-04. Estimated completion is 2019-01-18.
What interventions are being tested in trial NCT02134288?
The interventions under investigation include: Everolimus (DRUG), Belatacept (DRUG).
Who is sponsoring clinical trial NCT02134288?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.